Ataxia-Telangiectasia Group D Complementing Gene (ATDC) Promotes Lung Cancer Cell Proliferation by Activating NF-κB Pathway

Zhong-Ping Tang¹, Qian-Ze Dong¹, Quan-Zhe Cui¹, Paulie Papavassiliou², En-Di Wang², En-Hua Wang¹*

¹Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang City, China, ²Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America

Abstract

Previous studies suggested Ataxia-telangiectasia group D complementing gene (ATDC) as an oncogene in many types of cancer. However, its expression and biological functions in non-small cell lung cancer (NSCLC) remain unclear. Herein, we investigated its expression pattern in 109 cases of human NSCLC samples by immunohistochemistry and found that ATDC was overexpressed in 62 of 109 NSCLC samples (56.88%). ATDC overexpression correlated with histological type (p<0.0001), tumor status (p=0.0227) and histological differentiation (p=0.0002). Next, we overexpressed ATDC in normal human bronchial epithelial cell line HBE and depleted its expression in NSCLC cell lines A549 and H1299. MTI and colony formation assay showed that ATDC overexpression promoted cell proliferation while its depletion inhibited cell growth. Furthermore, cell cycle analysis showed that ATDC overexpression decreased the percentage of cells in G1 phase and increased the percentage of cells in S phase, while ATDC siRNA treatment increased the G1 phase percentage and decreased the S phase percentage. Further study revealed that ATDC overexpression could up-regulate cyclin D1 and c-Myc expression in HBE cells while its depletion down-regulated cyclin D1 and c-Myc expression in A549 and H1299 cells. In addition, ATDC overexpression was also associated with an increased proliferation index, cyclin D1 and c-Myc expression in human NSCLC samples. Further experiments demonstrated that ATDC up-regulated cyclin D1 and c-Myc expression independent of wnt/β-catenin or p53 signaling pathway. Interestingly, ATDC overexpression increased NF-κB reporter luciferase activity and p-κB protein level. Correspondingly, NF-κB inhibitor blocked the effect of ATDC on up-regulation of cyclin D1 and c-Myc. In conclusion, we demonstrated that ATDC could promote lung cancer proliferation through NF-κB induced up-regulation of cyclin D1 and c-Myc.

Introduction

Lung cancer is one of the leading causes of all cancer-related deaths worldwide and, in particular, non-small-cell lung cancer (NSCLC) constitutes the majority of the diagnosed cases [1,2]. Multiple factors including genetic, epigenetic and microenvironmental, play important roles in the survival and colonization of tumor cells at a distant tissue site, leading to the metastasis [3]. However, despite many experimental studies, an underlying molecular mechanism that governs the metastasis of individual tumors has not yet been fully understood. Due to the limited success of conventional therapies in achieving a long-term survival in lung cancer patients, research efforts have been focused on the biological pathways involved in tumor progression and neoplastic cell survival in order to identify potential therapeutic targets [4].

Ataxia-telangiectasia group D complementing gene (ATDC) is a member of the tripartite motif (TRIM) family [5]. TRIM proteins typically have a series of conserved domains including multiple zinc finger motifs and a leucine zipper motif. These proteins have been demonstrated to participate in cell growth regulation and development and have been implicated in several human diseases such as HIV infection and leukemia [6,7]. In particular, TRIM proteins such as TRIM8, TRIM22, TRIM38 and TRIM40 have been reported to engage in regulating NF-κB activation [8–11]. ATDC, also known as TRIM29, was initially identified in a search for the gene responsible for the genetic disorder ataxia-telangiectasia and was found to possess radiosensitivity suppressor functions [12]. Subsequent studies showed that ATDC was overexpressed in multiple types of cancers including pancreatic, gastric, bladder, colorectal, ovarian and endometrial cancers, as well as in plasma cell myeloma [13–21]. Whereas, its expression was apparently reduced in several other tumors, such as melanoma, breast, prostate, head and neck cancers [22–27]. Only one report described increased ATDC mRNA expression in association with high histological grade, large tumor size, extent of tumor invasion and lymph node metastasis in gastric cancer [15]. However, to the best of our knowledge, the protein expression of ATDC and its relationship with clinicopathological factors in primary lung cancers have never been characterized.

A recent study in a pancreatic adenocarcinoma cell line demonstrated that ATDC interacts with Disheveled-2 and the components of β-catenin destruction complex to stabilize β-
catenin and activate Wnt signaling, a crucial pathway that promotes tumor progression in many types of cancer [13]. Other studies suggested that ATDC binds p53 in the cytoplasm to sequester it from nucleus resulting in down-regulation of its target gene p21 [28]. In the A431 human squamous carcinoma cell line, ATDC was noted to interact with the intermediate-filament protein vimentin and with an inhibitor of protein kinase C, thereby acting as a component of the protein kinase C signal transduction pathway [29]. Altogether, these previous studies suggest that ATDC may function as an oncogene to promote cancer cell proliferation and invasion. However, the biological roles of ATDC in lung cancer cells have not yet been determined.

In order to address the above questions, we checked ATDC expression and tissue distribution in non-small-cell lung cancer by immunohistochemistry and analyzed its association with clinico-pathological parameters. We also investigated the roles of ATDC on cell proliferation and cell cycle progression using gain- or loss-of-function approaches. More importantly, we explored the potential mechanism by which ATDC functions to promote the proliferation of lung cancer cells.

Methods

Patients and Specimens

This study was conducted with the approval of the institutional review board at China Medical University. Written consent was given by the participants for their information to be stored in the hospital database for their specimens to be used in this study. And
all clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki. The primary tumor specimens were collected from 109 patients with squamous cell carcinoma (SCC) or adenocarcinoma of the lung who underwent complete surgical resection in the First Affiliated Hospital of China Medical University between 2001 and 2004. Large cell carcinoma, adenosquamous cell carcinoma or other NSCLC subtypes were excluded from this study. Follow-up information was obtained by reviewing the patients’ medical records. None of the patients had received radiotherapy or chemotherapy before surgical resection, and all the patients were treated with routine chemotherapy after the resection. All 109 cases were reviewed for histological subtype, differentiation, and tumor stage. The histological diagnosis and grade were evaluated on haematoxylin and eosin-stained sections according to the World Health Organization (WHO) guidelines of classification. Of 109 cases, 46 (42.2%) were SCC and 63 (57.8%) were adenocarcinoma. Lymph node metastases were identified in 44 (40.4%) of the 109 patients. The p-TNM staging system of the International Union against Cancer (7th Edition) was used to classify the cases.

**Table 1.** Expression of ATDC in the cases of NSCLC stratified by their clinicopathological parameters.

| Characteristics       | Number of patients | ATDC negative | ATDC positive | P      |
|-----------------------|--------------------|---------------|---------------|--------|
| **Age**               |                    |               |               |        |
| <60                   | 59                 | 27(45.76%)    | 32(54.24%)    | 0.5449 |
| ≥60                   | 50                 | 20(40.00%)    | 30(60.00%)    |        |
| **Gender**            |                    |               |               |        |
| Male                  | 61                 | 24(39.34%)    | 37(60.66%)    | 0.3696 |
| Female                | 48                 | 23(47.92%)    | 25(52.08%)    |        |
| **Histology**         |                    |               |               |        |
| Adenocarcinoma        | 63                 | 46(73.02%)    | 17(26.98%)    | <0.0001|
| Squamous cell carcinoma| 46                | 1(2.17%)      | 45(97.83%)    |        |
| **Differentiation**   |                    |               |               |        |
| Well                  | 35                 | 24(68.57%)    | 11(31.43%)    | 0.0002 |
| Moderate- Poor        | 74                 | 23 (31.08%)   | 51(68.92%)    |        |
| **TNM stage**         |                    |               |               |        |
| I                     | 48                 | 19(39.58%)    | 29(60.42%)    | 0.5085 |
| II+III                | 61                 | 28(45.90%)    | 33(54.10%)    |        |
| **Tumor status**      |                    |               |               |        |
| T1                    | 38                 | 22(57.89%)    | 16(42.11%)    | 0.0227 |
| T2 T3 T4              | 71                 | 25(35.21%)    | 46(64.79%)    |        |
| **Nodal status**      |                    |               |               |        |
| N0                    | 65                 | 25(38.46%)    | 40(61.54%)    | 0.2327 |
| N1 N2 N3              | 44                 | 22(50.00%)    | 22(50.00%)    |        |
| **Ki67**              |                    |               |               |        |
| Low                   | 49                 | 29(59.18%)    | 20(40.82%)    | 0.0022 |
| High                  | 60                 | 18(30.00%)    | 42(70.00%)    |        |
| **cyclin D1**         |                    |               |               |        |
| Low                   | 39                 | 25(64.10%)    | 14(35.90%)    | 0.0010 |
| High                  | 70                 | 22(34.14%)    | 48(64.86%)    |        |
| **c-Myc**             |                    |               |               |        |
| Low                   | 72                 | 37(51.39%)    | 35(48.61%)    | 0.0130 |
| High                  | 37                 | 10(27.03%)    | 27(72.97%)    |        |

doi:10.1371/journal.pone.0063676.t001

**Cell Culture and Treatment**

NHBE, A549, H1299, H157 and H460 cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). LH7 and LK2 cell lines were purchased from Shanghai Cell Bank of Chinese Academy of Science. The BE1 cell line was provided as a gift by Dr. J Zheng (Department of Pathology, Peking University School of Medicine). The BE1 cell line was established by Dr. J Zheng and Dr. WY Zhu in 1995 and now could be purchased from National Platform of Experimental Cell Resources for Sci-Tech (Peking, China). Cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum. Cells were grown on sterile tissue culture dishes and were passaged every 2 days using 0.25% trypsin (Invitrogen). NF-κB inhibitor BAY 11-7082 (10 μM, 6 hours) was purchased from Sigma Aldrich.

**Immunohistochemistry**

Surgically excised tumor specimens were fixed with 10% neutral formalin, embedded in paraffin and 4 μm thick sections were prepared. Immunostaining was performed using the avidin–biotin–peroxidase complex method (Ultra Sensitive TM, Maixin,
Immunohistochemical staining for Ki-67 (1:200 dilution) (cat.-MAB-0129, Maixin, Fuzhou, China), c-Myc (1:500 dilution) (cat.ab32, Abcam) and cyclin D1 (1:100 dilution) (cat.2978, Cell signaling technology, Boston, MA, USA) were also performed following the manufacturers’ instructions. Staining for all primary antibodies was performed at room temperature for 2 hours. Biotinylated goat anti-mouse serum IgG or biotinylated goat anti-rabbit serum IgG (ready-to-use) (cat.KIT-9922, Maixin, Fuzhou, China) was used as the second antibody. After washing, the sections were incubated with horseradish peroxidase-conjugated streptavidin-biotin, followed by 3, 3'-diaminobenzidine tetrahydrochloride to develop peroxidase reaction. Counterstaining was done with hematoxylin, and the sections were then dehydrated with ethanol before being mounted.

Two investigators independently evaluated all tumor slides. Five random fields were examined per slide, and 100 cells were evaluated per high magnification field (400 ×). Normal bronchial epithelium in the tumor sections was used as an internal negative control. Immunostaining of ATDC was scored following a semi-quantitative scale by evaluating the staining intensity and percentage of cells in representative tumor areas as compared to that observed in the control cells. Positive immunostaining was defined as a distinct cytoplasmatic staining of the tumor cells. The intensity of ATDC cytoplasmatic staining was further stratified as 0 (no staining), 1 (weak) and 2 (strong). Percentage scores were designated as 1 (1–25%), 2 (26–50%), 3 (51–75%) and 4 (76–100%). The scores of each tumor sample were multiplied to give a final score of 0 to 8 and the total expression of ATDC was determined as either negative or low expression (-), if the total score was <4, and as positive expression or high expression (+), if the total score was ≥4.

The immunohistochemical staining for Ki-67 was evaluated and scored as percentage of the immunoreactive cancer cells, with a total of 500 tumor cells examined per slide. The median value of this series (35%) was used as a threshold value to stratify the tumors into the group with a low (<35%) index and the one with a high (≥35%) index of cell proliferation. The expression of c-Myc and cyclin D1 was defined as high level of expression or low level according to the previous criteria [30,31].

Quantitative Real-time PCR (SYBR Green Method)

Quantitative real-time PCR was performed using SYBR Green PCR master mix with a total volume of 20 µl in 7900HT Fast Real-Time PCR System (Applied Biosystems). The reaction condition is as follow: 95°C for 30 seconds, 40 cycles of 95°C for 5 seconds and 60°C for 30 seconds. A dissociation step was applied to generate a melting curve to confirm the specificity of the amplification. β-actin transcripts were amplified and served as the reference. The relative levels of gene expression were represented as ΔCt = Ct Gene – Ct reference, and the fold change of gene expression was calculated by the 2-ΔΔCt method. Experiments were performed in triplicate.

The primer sequences were as follows:

- β-actin forward, 5’-ATAGGACAGCGCTGGATAGCAACGTC-3’,
- β-actin reverse, 5’-CACCTTCTACAAATGGACGTCGTTGGA-3’;
- ATDC forward, 5’-GACCCGGACACCATGAGA-3’;
- ATDC reverse, 5’-GAGGACGAGGGCTTGATAGA-3’.

Western Blot Analysis

Total proteins from NSCLC tissues and lung cancer cell lines were extracted in lysis buffer (Thermo Fisher Scientific, Rockford, IL) and quantified using the Bradford method. Fifty micrograms of protein were separated by SDS–PAGE (12%). After transferring,
the polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA) were incubated overnight at 4°C with the following antibodies: ATDC (1:1000; cat.17542-1-AP, Proteintech), β-actin (1:500; cat.612657), β-catenin (1:1000; cat.610154) (BD Transduction Laboratories), cyclin A2 (1:1000; cat.4656S), cyclin D1 (1:1000; cat.2978), cyclin E1 (1:1000; cat.2906), cyclin E2 (1:800; cat.4129), CDK2 (1:1000; cat.2546), CDK4 (1:1000; cat.3136), CDK6 (1:1000; cat.3136), p-Rb (Ser807/811) (1:500; cat.8516), P21 (1:800; cat.2947), p-IκB (Ser32) (1:500; cat.2859) (Cell signaling technology, Boston, MA, USA), c-Myc (1:1000; cat.ab32, Abcam), active β-catenin (1:500; cat.05-665, Millipore), p65 (1:500; sc-8008, Santa Cruz). After incubation with peroxidase-coupled anti-mouse (cat.sc-2005) or rabbit (cat.sc-2004) IgG (Santa Cruz Biotechnology) at 37°C for 2 hours, bound proteins were visualized using ECL (Thermo Fisher Scientific) and quantified using BioImaging Systems (UVP Inc., Upland, CA, USA). The relative protein levels were calculated in reference to β-actin as the loading control.

**Plasmid Transfection and Small Interfering RNA Treatment**

The pCMV6-ATDC plasmid was purchased from Origene. pCMV6 empty vector was used as a negative control. On-target plus siRNAs for ATDC (M-012409-01) and non-targeting siRNA #1 (D-001810-01) were purchased from Dharmacon (Lafayette, CO, USA). The plasmid and siRNA were transfected into cells using Attractene Transfection reagent (Qiagen, Hilden, Germany). Briefly, cells were seeded in a 6-well plate 24 hours before the experiment. The mRNA and protein levels of ATDC were determined 48 hours after transfection.
Cell Proliferation Test and Colony Formation Assay

Cell proliferation assay was performed using Cell Counting Kit-8 solution (Dojindo, Gaithersburg, MD) according to the manufacturer’s protocol. Briefly, cells were seeded at a concentration of $5 \times 10^3$ cells/100 μl/well in 96-well culture plates and treated with 10 μl/well of Cell Counting Kit-8 solution during the last 4 hours of the culture. Optical density of the wells was measured at 450 nm wavelength using a microplate reader.

For colony formation assay, cells were planted into three 6-cm cell culture dishes ($1 \times 10^3$ cells per dish) and incubated for 12 days. Plates were washed with PBS and stained with Giemsa. The number of colonies with more than 50 cells was counted.

Cell Cycle Analysis

Cells ($5 \times 10^3$) were seeded into a 6 cm tissue culture dish. After 12 hour incubation, cells were treated with serum starvation for 24 hours before transfection with indicated doses of plasmids or siRNA. At the indicated time points, cells were harvested, fixed in 1% paraformaldehyde, washed with phosphate buffered saline (PBS) and stained with 5 mg/ml propidium iodide (Roche, Indianapolis, IN) for 30 minutes at room temperature. The stained cells were collected and analyzed using BD flow cytometry systems.

Luciferase Reporter Assay

Reporter gene transfection and luciferase activity assay were performed as follow: cells in confluent growth on a 24 well plate were co-transfected with the firefly luciferase reporter (0.2 μg)
along with the Renilla luciferase reporter (Promega Co) (0.02 μg) for 12 hours using an attractene reagent (Qiagen) according to the protocols provided by manufacturers. The reporter plasmids of TOP/FLASH, p53 and NF-κB were purchased from Biotime Biotechnology, China. The luciferase activity was measured in cellular extracts using a dual luciferase reporter gene assay kit (Promega, CA, USA). The relative activity of the reporter gene was calculated by dividing the signals from firefly luciferase reporter by the signals obtained from Renilla luciferase reporter.

Statistical Analysis

SPSS version 16.0 for Windows was used for all statistical analyses. The Chi-squared test was used to examine possible correlations between ATDC expression and clinicopathologic factors. The Student’s t-test was used to test the difference between the groups and p-values were based on the two-sided statistical analyses, with a p-value of <0.05 designating statistical significance.

Results

Overexpression of ATDC Protein in Non-small Cell Lung Cancer Tissues and its Relationship with Clinicopathological Factors

In order to investigate ATDC protein levels in lung cancer, we examined ATDC expression in a panel of 109 NSCLC specimens and 20 paired homologous normal lung tissues using immunohistochemistry. Overexpression of ATDC was noted in 62 (56.88%) out of 109 NSCLC specimens, and the ATDC protein was primarily localized in the cytoplasm of the tumor cells (Figure 1C–F). No or weak staining signals were detected in the normal lung tissues and the normal bronchial epithelia adjacent to the tumor (Figure 1A–B).

The relationship between ATDC expression and multiple clinicopathologic parameters was also analyzed. As shown in Table 1, a significant association was observed between ATDC overexpression and the extent of the primary tumor (T1 versus T2–T4: 42.11% versus 64.79%, p = 0.0227), histological differentiation (well differentiation versus moderate/poor differentiation: 31.43% versus 68.92%, p = 0.0002) and histological types (squamous cell carcinoma versus adenocarcinoma: 97.83% versus 26.90%, p < 0.0001). No statistically significant difference was found between ATDC overexpression and patient age (p = 0.5449), gender (p = 0.3696), nodal status (p = 0.2327) or TNM stage (p = 0.5065).

ATDC Promotes Cell Proliferation in Lung Cancer Cell Lines

Expression of ATDC was analyzed by real-time PCR and western blot assays in a panel of lung cancer cell lines and in a normal bronchial epithelial cell line HBE (Figure 2A–B). We found that both ATDC mRNA and protein expression levels in NSCLC cell lines were much higher than that in HBE, especially in A549 and H1299 cell lines. In order to investigate a possible role of ATDC in the cell growth of lung cancer, we transfected an ATDC cDNA expression construct into HBE cells and applied a pool consisting of three ATDC-targeting siRNAs to knockdown ATDC expression in both A549 and H1299 cell lines. In Figure 2C–D, HBE cells demonstrated a significant increase in ATDC expression after ATDC transfection, while ATDC-specific siRNA efficiently blocked ATDC expression in A549 and H1299 cell lines.

MTT assay showed that transfection of ATDC cDNA into HBE cells promoted cell growth compared with control (transfection of empty vectors) (HBE control versus ATDC cDNA: 1.06±0.05 versus 1.41±0.05, p<0.05). The effect of ATDC on proliferation capacity was also analyzed by using colony formation assay. ATDC overexpression in HBE cells led to a remarkable increase in colony numbers (HBE control versus ATDC cDNA: 221±13 versus 441±9, p<0.05). On the other hand, the cell proliferation rate (A549 NC versus siATDC: 1.23±0.03 versus 0.84±0.03; H1299 NC vs siATDC: 1.72±0.01 versus 1.19±0.02; p<0.05) and colony formation ability (A549 NC versus siATDC: 400±12 versus 130±14; H1299 NC vs siATDC: 258±20 versus 119±17; p<0.05) were attenuated in A549 and H1299 cells with ATDC knockdown (Figure 3). These results altogether suggest that ATDC could modulate lung cancer cell proliferation.

ATDC Facilitates G1/S Transition and Up-regulates Cyclin D1 and c-Myc Expression in Lung Cancer Cells

Cell cycle analysis by fluorescence activated cell sorting (FACS) was performed in ATDC overexpressing HBE cells and in ATDC depleted A549 and H1299 cells (Figure 4). ATDC overexpression decreased the percentage of cells in the G1 phase (HBE control versus ATDC cDNA: 68.04±0.04% versus 57.74±0.51%, p<0.05) and increased the percentage of cells in S phase (HBE control versus ATDC cDNA: 12.48%±0.74% versus 27.62%±0.61%, p<0.05). Conversely, ATDC siRNA treatment increased the cells in the G1 phase (A549 NC versus siATDC: 64.99%±0.37% versus 75.99%±0.72%; H1299 NC versus siATDC: 52.66%±1.47% versus 63.80%±1.13%; p<0.05) and decreased the cells in the S phase (A549 NC versus siATDC: 29.59%±0.45% versus 9.24%±0.06%; H1299 NC versus siATDC: 37.55%±3.13% versus 20.80±3.11%; p<0.05) com-
pared with control. These results suggest that ATDC may promote cell cycle progression through the G1/S boundary.

To investigate the mechanism of cell cycle progression regulated by ATDC in lung cancer, we examined the effect of ATDC on cyclin A, cyclin D1, cyclin E, CDK2, CDK4, CDK6, p-Rb and c-Myc in lung cancer cell lines. As shown in Figure 5, western blotting analysis revealed that ATDC overexpression up-regulated the protein levels of cyclin D1, CDK4, CDK6, p-Rb and c-Myc in HBE cells, while knockdown of ATDC decreased expression of these proteins in A549 and H1299 cells. Altogether, these results suggest that ATDC may promote G1/S transition via up-regulating cyclin D1 and c-Myc expression.

Figure 6. ATDC expression correlates directly with index of Ki-67 labeling and expression of cyclin D1 and c-Myc in NSCLC tissues. Immunohistochemical staining of ATDC (A and B), cyclin D1 (C and D), c-Myc (E and F) and Ki67 (G and H) in NSCLC specimens. A, C, E and G indicate a representative case with positive ATDC demonstrating a high level of cyclin D1 and c-Myc, a high labeling index of ki67, while B, D, F and H represent a case with negative ADTC and corresponding negative cyclin D1 and c-Myc staining or low level of ki67 labeling.

doi:10.1371/journal.pone.0063676.g006

ATDC Expression Correlates with Ki67 Labeling Index, Cyclin D1 and c-Myc Levels in NSCLC Tissues

We examined the relationship between the level of total ATDC protein and the proliferation index (Ki67 labeling) in NSCLC. We found that cases with a high level of ATDC protein expression tended to show a high proliferation index, in comparison with those with a low level of ATDC (p = 0.0022) (Figure 6). Immunostaining for cyclin D1 and c-Myc was also performed in NSCLC specimens and their associations with ATDC expression were analyzed (Figure 6). As shown in Table 1, ATDC overexpression correlated with a high level of cyclin D1 (p = 0.0010) and c-Myc expression (p = 0.0150).
ATDC Up-regulates Cyclin D1 and c-Myc through Activation of NF-κB Pathway

Since both cyclin D1 and c-Myc were downstream targets of NF-κB, we examined the protein expression of p65, p-IκB and NF-κB luciferase activity to assess if ATDC could regulate the activation of NF-κB pathway (Figure 8A–B). It appeared that ATDC overexpression in HBE cells up-regulated NF-κB reporter luciferase activity, and correspondingly, ATDC depletion in A549 and H1299 cells down-regulated its activity. On the other hand, the level of p-IκB was up-regulated in HBE cells transfected with ATDC and down-regulated in A549 and H1299 cells depleted of endogenous ATDC, although there was no significant change of total p65 level in these cells. These results suggest a possible involvement of NF-κB activation in ATDC induced up-regulation of cyclin D1 and c-Myc. Bay 11-7082, which inhibits phosphorylation and degradation of IκBα to block NF-κB activation, was also utilized in HBE cells transfected with ATDC to confirm the effect of NF-κB activation. As shown in Figure 8C, NF-κB inhibitor reversed the effect of ATDC on cyclin D1, c-Myc and p-Rb in HBE cells. Therefore, NF-κB activation may be a prerequisite for ATDC induced up-regulation of cyclin D1 and c-Myc.

Discussion

ATDC, located at chromosome 11q22–23, belongs to the tripartite motif (TRIM) protein family (also known as the RBCC family) and was overexpressed in variety of different cancers [13–21]. Conversely, other studies reported a diminished expression of ATDC in a few other neoplasms, including breast, head and neck and prostate cancers [22–27]. Therefore, the expression pattern of ATDC seems to be paradoxically distinct among various types of cancers and the significance of ATDC in cancers, as well as its biological function in carcinogenesis and cancer cell progression, may vary depending upon the tissue origin of the neoplasm. A recent report described a correlation of ATDC mRNA expression with poor histological grade, large tumor size, extent of tumor invasion, and lymph node metastasis in gastric cancer [15]. In our study, we demonstrated that ATDC protein expression in lung cancer tissues was higher than that in normal lung tissues, and the expression of ATDC significantly correlated with histological type, tumor status and differentiation. These findings were generally consistent with previous studies which suggested a possible oncogenic function of ATDC in certain types of cancers.
Previous studies regarding the biological functions of ATDC exhibited that ATDC expression was associated with cell proliferation and tumor growth, suggesting that ATDC might act as a tumor promoter [13,28]. To further investigate the functions of ATDC in lung cancer, we initially examined the expression level of ATDC in several lung cancer cell lines and immortalized human bronchial cell line NHBE by real-time PCR and western blot analysis. With these assays, we were able to confirm a minimal to essentially absent ATDC expression in HBE cells and a variable increase in ATDC expression in lung cancer cell lines.

**Figure 8. ATDC up-regulates Cyclin D1 and c-Myc via activation of NF-κB signaling pathway.**

A. ATDC overexpression up-regulated NF-κB reporter luciferase activity in HBE cells and ATDC depletion inhibited NF-κB reporter luciferase activity in both A549 and H1299 cells. B. ATDC transfection increased p-IκB expression in HBE cells and ATDC depletion decreased the level of p-IκB in A549 and H1299 cells. C. NF-κB inhibitor Bay 11-7082 completely blocked NF-κB reporter luciferase activity and reversed the effect of ATDC on cyclin D1, c-Myc and p-Rb up-regulation.

doi:10.1371/journal.pone.0063676.g008
cell lines at both transcriptional and translational levels. By applying gain- or loss-of-function approaches in HBE, A549 and H1299 cell lines in the current study, we hoped to shed light on the biological functions of ATDC in regulating neoplastic proliferation of lung cancer cells. Overexpression of exogenous ATDC promoted cell proliferation rate and colony formation in the HBE cell line that contained minimal endogenous ATDC. In addition, ATDC knockdown in the cells with high levels of ATDC showed impaired cell proliferation rate and colony formation. Cell cycle analysis showed that ATDC overexpression increased S phase cells and decreased G1 phase cells, suggesting that ATDC might facilitate G1 to S phase transition during cell cycle progression.

To better understand the role of ATDC in cell cycle regulation, we investigated the effect of ATDC overexpression and knockdown on a series of cell cycle-related molecules including cyclin A, cyclin D1, cyclin E, CDK2, CDK4, CDK6, p-Rb and c-Myc. Knockdown of ATDC reduced the protein levels of cyclin D1, p-Rb, CDK4, CDK6 and c-Myc in the 2 lung cancer cell lines with endogenous expression of ATDC. On the other hand, the expression of the above proteins was up-regulated after ATDC transfection in HEB cells. A few previous studies showed that cyclin D-Cdk4/6 complex partially phosphorylated Rb to inactivate its function as a transcriptional repressor and thus release transcription factor E2F, enabling the expression of target genes essential for G1 to S phase transition and DNA synthesis [32]. In accordance, overexpression of cyclin D1 shortened the G1 phase of the cell cycle and suppression of cyclin D1 prevented the cells from entry into S phase resulting in their arrest at G1 phase [33–35]. Furthermore, overexpression of c-Myc in growing cells was also reported to lead to a shortened G1 phase [36], whereas reduced expression causes lengthening of the cell cycle [37]. In our study, cell cycle arrest at G1 phase after ATDC knockdown in the 2 lung cancer cell lines (A549 and H1299) seems to be in keeping with corresponding down-regulation of cyclin D1 and c-Myc. Therefore, it may be that ATDC accelerates G1/S phase transition and promotes lung cancer cell proliferation by enhancing the expression of cyclin D1 and c-Myc.

In order to answer if the regulatory effect of ATDC on cell cycle progression in NSCLC is mediated by cyclin D1 and c-Myc upregulation in vivo, we examined Ki67 index, cyclin D1 and c-Myc expression in NSCLC tissues. Statistically significant correlations of ATDC expression were observed with level of proliferation index, cyclin D1 and c-Myc expression in neoplastic tissues. In conjunction with the data obtained from lung cancer cell lines, it is highly likely that ATDC may upregulate cyclin D1 and c-Myc and in turn accelerate cell cycle progression in NSCLC.

Cumulative evidence suggests that lung cancer cells use multiple, and perhaps redundant pathways to maintain their survival [30]. Recent investigations have revealed that ATDC modulates cancer progression through wnt/β-catenin activation or p53 inhibition [13,28,39,40]. Cyclin D1 and c-Myc have been well documented to be regulated by nuclear β-catenin or a p53 target p21 [31,41–43]. It is thus questioned if ATDC induced cyclin D1 and c-Myc up-regulation in lung cancer cells results from wnt activation or p53 inhibition. To test these possibilities, we evaluated the level of wnt/β-catenin and p53 activity in ATDC knockdown and overexpressing cells, and surprisingly, no significant changes of wnt/β-catenin and p53 activity were observed with alterations of ATDC level. Therefore, ATDC seems not being involved in regulating p53 or wnt signaling in lung cancer cell lines used in this study, despite its effect on cell proliferation and cell cycle progression.

NF-κB has been demonstrated to regulate many genes including cyclin D1 and c-Myc [44–46], and play important roles in tumorigenesis, cell proliferation and metastasis in cancers such as colon, lung and breast cancer [47–49]. TRIM proteins such as TRIM8, TRIM22 and TRIM38 have been reported to engage in NF-κB inhibition [5–10]. Interestingly, TRIM40 has been noted to physiologically bind to NEDD8 and promote the neddylation of IKKγ, which is a crucial Negative regulator of NF-κB activation [11]. As a member of TRIM family, ATDC might possess a function in regulating NF-κB activity. As predicted, ATDC appeared to up-regulate p-IκB protein level in our further analysis. The activities of NF-κB luciferase reporter constructs were significantly enhanced by ATDC overexpression in HBE cells, and were diminished by ATDC knockdown in A549 and H1299 cells. This suggests a possible involvement of NF-κB pathway in ATDC induced cyclin D1 and c-Myc up-regulation and cell proliferation in lung cancer cells. When NF-κB inhibitor BAY 11-7082 was applied to HBE cells treated with ATDC transfection, the effects of ATDC on the levels of cyclin D1 and c-Myc were apparently abolished. These findings suggest that the role of ATDC in regulating cyclin D1 and c-Myc as well as cell cycle progression may be by means of NF-κB activation.

In conclusion, we, for the first time, demonstrate the expression and biological functions of ATDC in NSCLC. Briefly, ATDC could promote lung cancer proliferation through NF-κB induced up-regulation of cyclin D1 and c-Myc. The ATDC molecule may be used as a potential therapeutic target in the treatment of certain NSCLCs that express the protein. However, such a therapeutic approach needs to be further investigated and validated by additional clinical and experimental studies.

Acknowledgments

We thank Dr. J Zheng (Department of Pathology, Peking University School of Medicine) for providing the BE1 cell line.

Author Contributions

Conceived and designed the experiments: ZPT QZD EHW. Performed the experiments: ZPT QZC. Contributed reagents/materials/analysis tools: ZPT QZC. Wrote the paper: ZPT PP EDW.

References

1. Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1: 49–58.
2. Jemal A, Siegel R, Xu J, Ward E Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
3. Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283: 139–146.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98.
5. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, et al. (2001) The tripartite motif family identifies cell compartments. EMBO J 20: 2140–2151.
6. Zhao G, Ke D, Vu T, Ahn J, Shah VB, et al. Rhesus TRIM5alpha disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog 7: e1002009.
7. Oliveira NM, Trikha R, McKnight A A novel envelope mediated post entry restriction of murine leukemia virus in human cells is Ref1/TRIM5alpha independent. Retrovirology 7: 81.
8. Li Q, Yan J, Mao AP, Li C, Ran Y, et al. Tripartite motif β (TRIMβ) modulates TNFα-induced and IL-1β beta-triggered NF-kappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc Natl Acad Sci U S A 108: 19341–19346.
9. Lin XL, Lei XR, Wang JZ, Huang T, [Identification A novel protein TRIM38 that activates NF-kappaB signaling pathway], Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 25: 60–62.

10. Yu S, Gao B, Duan Z, Xu W, Xiong S Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-kappaB activator. Biochem Biophys Res Commun 410: 247–251.

11. Noguchi K, Okumura F, Takahashi N, Kataoka A, Kiyama Y, et al. TRIM40 promotes neddylation of IKKgamma and is downregulated in gastrointestinal cancers. Carcinogenesis 32: 993–1004.

12. Kapp LN, Painter RB, Yu LC, van Loon N, Richard CW, 3rd, et al. Cloning of a candidate gene for ataxia-telangiectasia group D. Am J Hum Genet 51: 45–54.

13. Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, et al. (2009) Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15: 207–219.

14. Hwang S, Seo J, Panzarella J, Loewen GM, Baumann H (2006) Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung Cancer 53: 129–142.

15. Kosaka Y, Inoue H, Ohmachi T, Yokote T, Matsumoto T, et al. (2007) Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol 14: 2543–2549.

16. Dynnikov I, Kruhoffer M, Thykaer T, Marcussen N, Jensen JL, et al. (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists diverging histopathological classification. Cancer Res 64: 4049–4056.

17. Glavak OK, Rodriguez LM, Soballe P, DeNobile J, Clarck J, et al. (2006) Gene expression patterns distinguish colonspecifically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15: 2253–2262.

18. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaka K, et al. (2006) Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 12: 3057–3063.

19. Santin AD, Zhang F, Bellone S, Palmieri M, Cane S, et al. (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112: 14–25.

20. Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, et al. (2001) Global expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745–1757.

21. Yuan Z, Tsukiyama T, Sato T, Kondo T, Cheng J, et al. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim Biophys Acta 1813: 1245–1253.

22. Chuang Bing Du Xue Za Zhi 25: 60–62.

23. Chuang Bing Du Xue Za Zhi 25: 60–62.

24. Wu J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, et al. (2001) Human expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745–1757.

25. Yu YP, Landsholt D, Jing L, Nelson J, Ren B, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790–2799.

26. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, et al. (2001) Human prostate cancer and benign prostate hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683–4690.

27. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, et al. (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499–4506.

28. Zhang P, Zhang Z, Zhou X, Qin W, Chen F, et al. (2006) Identification of genes associated with cip1aatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 6: 224.

29. Nacht M, Ferguson AT, Zhang W, Petrozzolo JM, Cook RP, et al. (1999) Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 59: 5464–5470.

30. Smith AP, Hsieh K, Becker D (2002) Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4: 1018–1029.

31. Li YJ, Wei ZM, Meng Y, Ji XN, et al. (1999) ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol 30: 3004–3015.

32. Brzoska PM, Chen H, Zhu Y, Levin NA, DiStefani MH, et al. (1995) The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor. Proc Natl Acad Sci U S A 92: 7624–7628.

33. Burke L, Flies DB, Guinee DG, Brumbilla E, Freedman AN, et al. (2005) Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 11: 232–241.

34. Li Y, Wei Y, Meng Y, Ji XN (2005) Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol 11: 2117–2123.

35. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymerase, aberrant splicing and cancer risk. Oncogene 25: 1620–1629.

36. Ratschiller D, Heigl J, Gugger M, Kappeler A, Pirnia F, et al. (2003) Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 21: 2003–2009.

37. Roy PG, Thompson AM (2006) Cyclin D1 and breast cancer. Breast 15: 718–727.

38. Keum JS, Kong G, Yang SC, Shin DH, Park SS, et al. (1999) Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 81: 127–132.

39. Kann J, Watson JW, Lowe AD, Green SM, Vedeckis W (1989) Regulation of cell cycle duration by c-myc levels. Oncogene 4: 773–787.

40. Shichiri M, Hanson KD, Sedivy JM (1993) Effects of c-myc expression on proliferation, quiescence, and the Go to G1 transition in nontransformed cells. Cell Growth Differ 4: 93–104.

41. Ames BN, Gold LS (1989) The causes and prevention of cancer: the role of environment. Biotherapy 11: 205–220.

42. Yuan Z, Peng L, Radhakrishnan R, Seto E. Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein. J Biol Chem 285: 39329–39338.

43. Shu T, Tsukiyama T, Sato T, Kondo T, Cheng J, et al. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim Biophys Acta 1813: 1245–1253.

44. Udhayakumar G, Jayanti V, Devaraj N, Devaraj H (2007) Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer. Mol Carcinog 46: 807–817.

45. Tung JN, Chiang CC, Tsai YY, Chou YY, Yeh KT, et al. CyclinD1 protein expression in pterygia is associated with beta-catenin protein localization. Mol Vis 16: 2733–2738.

46. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414.

47. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241–246.

48. Chen C, Edelstein LG, Gelinus C (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol 20: 2687–2695.

49. Guttridge DC, Allmanc CE, Reuther Y, Festell RG, Baldwin AS, Jr. (1999) NF- kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785–5799.

50. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, et al. (2007) Incitivation of NF-kappaB by 3,3’-dichlorobenzenethione contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 6: 2757–2765.

51. Teow GW, Lorimer EL, Berg TJ, Zhi H, Li R, et al. (2008) SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma. J Biol Chem 283: 963–976.

52. Fernandez-Majada V, Aguiller A, Vilaumea V, Vilardell F, Roberts-Moreno A, et al. (2007) Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci U S A 104: 276–281.